AYA.AX Artrya Limited ASX up 25.40% pre-market 09 Apr 2026: AI imaging momentum

AYA.AX stock jumps to A$3.90 in pre-market trade on 09 Apr 2026, a 25.40% intraday rise that follows higher volume and renewed investor interest in AI imaging. Artrya Limited (AYA.AX) listed on the ASX offers Salix, an AI-driven coronary CTCA reader, and this move reflects demand for clinical AI tools in healthcare. Trading volume of 1,207,294 shares tops the 50-day average of 496,698, signalling stronger market attention ahead of further commercial updates. Meyka AI provides this AI-powered market analysis to link the price move with fundamentals and technicals.

AYA.AX stock market snapshot and price action

AYA.AX stock opened at A$3.28 and hit a day high of A$4.04 before settling at A$3.90 in pre-market. Market capitalisation is A$443,820,000 with 113,800,000 shares outstanding.

Volume today is 1,207,294, implying relative volume of 2.57 versus the average 496,698. Year range is A$0.57–A$5.24, and the 50-day average is A$3.29.

AYA.AX stock business model and AI opportunity

Artrya Limited (AYA.AX) sells Salix, cloud software that automates coronary artery disease detection from CT angiography. The company targets hospitals and imaging centres with a subscription and per-study revenue mix.

Adoption hinges on regulatory approvals and payer/institutional contracts. Growing demand for AI in medical imaging gives Artrya a clear market opportunity, but sales scale and conversion timing remain the key tests.

AYA.AX stock financials and valuation metrics

Latest reported EPS is -0.17 and reported PE stands at -22.94, reflecting negative earnings. Price to book is 5.49 and cash per share is 0.61.

Key ratios show a strong current ratio of 37.11, negligible debt to equity of 0.006, and high R&D intensity at 84.34% of revenue. These metrics underline heavy investment in product and low leverage, but also stretched margins and very high price-to-sales multiples.

AYA.AX stock technicals and trading signals

Short-term momentum indicators are bullish: RSI is 63.64 and CCI is 197.38 (overbought). MACD histogram is positive at 0.08 and the stock trades above its 50-day average of A$3.29.

Bollinger upper band sits at A$3.74 and ATR is A$0.31, which suggests higher intraday volatility after the gap up. Traders should watch support near A$3.15 (middle band) and resistance near the year high A$5.24.

Meyka AI grade and AYA.AX stock forecast

Meyka AI rates AYA.AX with a score out of 100: 60.14 / 100 — Grade B (HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects monthly A$3.05 (–21.79% vs A$3.90), quarterly A$4.36 (+11.79%), and yearly A$7.41 (+90.00%). Forecasts are model-based projections and not guarantees.

AYA.AX stock risks and catalysts

Near-term catalysts include commercial contracts, regulatory milestones, and clinical validation publications that would support revenue growth. Positive updates could push the stock toward the quarterly forecast of A$4.36.

Risks include slow hospital procurement cycles, reimbursement uncertainty, and high operating expenses that keep EPS negative. Watch monthly revenue updates and cash burn closely.

Final Thoughts

Key takeaways for AYA.AX stock: the pre-market rise to A$3.90 on 09 Apr 2026 reflects renewed interest in Artrya Limited’s AI imaging product and a volume spike above 1.2 million shares. Fundamentals show low leverage, cash per share A$0.61, and continued negative EPS -0.17. Technicals point to short-term momentum, while Meyka AI’s model gives a near-term downside to A$3.05 and a one-year upside to A$7.41. Our Meyka AI grade is 60.14 / 100 (B, HOLD), balancing growth potential against execution and margin risks. Investors focused on AI stocks should treat AYA.AX as a growth-play with binary catalysts and monitor quarterly commercial progress, cash runway, and regulatory news. For direct company details see the official site and our Meyka stock page for live updates: Artrya website and Artrya on Meyka. Forecasts are model projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.